Taiwan Dr Chen-Yu Cheng, founder and chairman at Formosa Laboratories & Pharmaceuticals, is leading a strategic transition from generic API manufacturing toward high- value CDMO services and innovative drug development. By leveraging proprietary nanotechnology and antibody-drug conjugate platforms, the group is diversifying into injectables and considering the US market. Dr Cheng…
Taiwan Dr John Chang, Chief Executive Officer of the Formosa Cancer Foundation and a distinguished medical oncologist at Chang Gung Memorial Hospital, provides a comprehensive strategic analysis of Taiwan’s oncology landscape. He delineates the evolution of precision medicine, the economic intricacies of national health reimbursement, and the critical role of patient…
Taiwan C.Y. Cheng, chairman and president of Formosa Laboratories, shares exciting news about the establishment of a new drug development company, Formosa Pharmaceuticals. He explains how the know-how gained from running a successful international API production business will help Formosa avoid the typical mistakes that young R&D companies face. Mr. Cheng,…
API Industry Formosa Laboratories is one of Taiwan’s international pioneers in small molecules, entering the global arena at a very early stage. How did that decision come about? Generally speaking, Taiwan’s API industry decided to go global long before the formulation sector did. The reason is simple: the local market for APIs…
See our Cookie Privacy Policy Here
